219 related articles for article (PubMed ID: 26693692)
1. The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane.
Fisher ML; Adhikary G; Grun D; Kaetzel DM; Eckert RL
Mol Carcinog; 2016 Dec; 55(12):2024-2036. PubMed ID: 26693692
[TBL] [Abstract][Full Text] [Related]
2. Survival of skin cancer stem cells requires the Ezh2 polycomb group protein.
Adhikary G; Grun D; Balasubramanian S; Kerr C; Huang JM; Eckert RL
Carcinogenesis; 2015 Jul; 36(7):800-10. PubMed ID: 25969142
[TBL] [Abstract][Full Text] [Related]
3. Verification of EZH2 as a druggable target in metastatic uveal melanoma.
Jin B; Zhang P; Zou H; Ye H; Wang Y; Zhang J; Yang H; Pan J
Mol Cancer; 2020 Mar; 19(1):52. PubMed ID: 32127003
[TBL] [Abstract][Full Text] [Related]
4. EZH2 activates CHK1 signaling to promote ovarian cancer chemoresistance by maintaining the properties of cancer stem cells.
Wen Y; Hou Y; Yi X; Sun S; Guo J; He X; Li T; Cai J; Wang Z
Theranostics; 2021; 11(4):1795-1813. PubMed ID: 33408782
[No Abstract] [Full Text] [Related]
5. PTEN Is Fundamental for Elimination of Leukemia Stem Cells Mediated by GSK126 Targeting EZH2 in Chronic Myelogenous Leukemia.
Zhou J; Nie D; Li J; Du X; Lu Y; Li Y; Liu C; Dai W; Wang Y; Jin Y; Pan J
Clin Cancer Res; 2018 Jan; 24(1):145-157. PubMed ID: 29070525
[No Abstract] [Full Text] [Related]
6. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
[TBL] [Abstract][Full Text] [Related]
7. NFIB Mediates BRN2 Driven Melanoma Cell Migration and Invasion Through Regulation of EZH2 and MITF.
Fane ME; Chhabra Y; Hollingsworth DEJ; Simmons JL; Spoerri L; Oh TG; Chauhan J; Chin T; Harris L; Harvey TJ; Muscat GEO; Goding CR; Sturm RA; Haass NK; Boyle GM; Piper M; Smith AG
EBioMedicine; 2017 Feb; 16():63-75. PubMed ID: 28119061
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth.
Barsotti AM; Ryskin M; Zhong W; Zhang WG; Giannakou A; Loreth C; Diesl V; Follettie M; Golas J; Lee M; Nichols T; Fan C; Li G; Dann S; Fantin VR; Arndt K; Verhelle D; Rollins RA
Oncotarget; 2015 Feb; 6(5):2928-38. PubMed ID: 25671303
[TBL] [Abstract][Full Text] [Related]
9. Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target.
Wen Y; Cai J; Hou Y; Huang Z; Wang Z
Oncotarget; 2017 Jun; 8(23):37974-37990. PubMed ID: 28415635
[TBL] [Abstract][Full Text] [Related]
10. EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells.
Mu Z; Li H; Fernandez SV; Alpaugh KR; Zhang R; Cristofanilli M
J Exp Clin Cancer Res; 2013 Sep; 32(1):70. PubMed ID: 24294976
[TBL] [Abstract][Full Text] [Related]
11. Sulforaphane suppresses the growth of glioblastoma cells, glioblastoma stem cell-like spheroids, and tumor xenografts through multiple cell signaling pathways.
Bijangi-Vishehsaraei K; Reza Saadatzadeh M; Wang H; Nguyen A; Kamocka MM; Cai W; Cohen-Gadol AA; Halum SL; Sarkaria JN; Pollok KE; Safa AR
J Neurosurg; 2017 Dec; 127(6):1219-1230. PubMed ID: 28059653
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic modifications in cutaneous malignant melanoma: EZH2, H3K4me2, and H3K27me3 immunohistochemical expression is enhanced at the invasion front of the tumor.
Kampilafkos P; Melachrinou M; Kefalopoulou Z; Lakoumentas J; Sotiropoulou-Bonikou G
Am J Dermatopathol; 2015 Feb; 37(2):138-44. PubMed ID: 25614949
[TBL] [Abstract][Full Text] [Related]
13. Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.
Tiffen JC; Gunatilake D; Gallagher SJ; Gowrishankar K; Heinemann A; Cullinane C; Dutton-Regester K; Pupo GM; Strbenac D; Yang JY; Madore J; Mann GJ; Hayward NK; McArthur GA; Filipp FV; Hersey P
Oncotarget; 2015 Sep; 6(29):27023-36. PubMed ID: 26304929
[TBL] [Abstract][Full Text] [Related]
14. Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells.
Zeng D; Liu M; Pan J
Oncotarget; 2017 Jan; 8(2):3396-3411. PubMed ID: 27926488
[TBL] [Abstract][Full Text] [Related]
15. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
[TBL] [Abstract][Full Text] [Related]
16. Sulforaphane inhibits PRMT5 and MEP50 function to suppress the mesothelioma cancer cell phenotype.
Ezeka G; Adhikary G; Kandasamy S; Friedberg JS; Eckert RL
Mol Carcinog; 2021 Jul; 60(7):429-439. PubMed ID: 33872411
[TBL] [Abstract][Full Text] [Related]
17. Human bronchial carcinoid tumor initiating cells are targeted by the combination of acetazolamide and sulforaphane.
Bayat Mokhtari R; Baluch N; Morgatskaya E; Kumar S; Sparaneo A; Muscarella LA; Zhao S; Cheng HL; Das B; Yeger H
BMC Cancer; 2019 Aug; 19(1):864. PubMed ID: 31470802
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target.
Cao J; Pontes KC; Heijkants RC; Brouwer NJ; Groenewoud A; Jordanova ES; Marinkovic M; van Duinen S; Teunisse AF; Verdijk RM; Snaar-Jagalska E; Jochemsen AG; Jager MJ
J Pathol; 2018 Aug; 245(4):433-444. PubMed ID: 29732557
[TBL] [Abstract][Full Text] [Related]
19. Predicting the Correlation of EZH2 and Cancer Stem Cell Markers in Esophageal Squamous Cell Carcinoma.
Karami Madani G; Rad A; Molavi M; Ardalan Khales S; Abbaszadegan MR; Forghanifard MM
J Gastrointest Cancer; 2018 Dec; 49(4):437-441. PubMed ID: 28681114
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of EZH2 by chemo- and radiotherapy agents and small molecule inhibitors induces cell death in castration-resistant prostate cancer.
Wu C; Jin X; Yang J; Yang Y; He Y; Ding L; Pan Y; Chen S; Jiang J; Huang H
Oncotarget; 2016 Jan; 7(3):3440-52. PubMed ID: 26657505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
